Pancreaticobiliary cancer: The future aspects of medical oncology

16Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Pancreatic cancer is one of the most common and most lethal cancers in the Western world with a median survival of approximately 3 months. Thus far, the results of anti-cancer treatment have been dismal, with a median survival of only 20 months in resectable pancreatic cancer, and 6 months in advanced disease. Although combined chemoradiation results in improved local control, it has only a modest impact on survival due to the development of distal metastases. In this review we will discuss the progress made in the treatment of pancreatic cancer over the past few years and discuss future therapies such as: immunoradiotherapy, matrix metalloproteinase inhibitors, antiangiogenesis therapies, gene therapy, immunotherapy, ONYX015, and farnesylation inhibitors.

Cite

CITATION STYLE

APA

Van Riel, J. M. G. H., Giaccone, G., & Pinedo, H. M. (1999). Pancreaticobiliary cancer: The future aspects of medical oncology. In Annals of Oncology (Vol. 10). Springer Netherlands. https://doi.org/10.1093/annonc/10.suppl_4.S296

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free